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Pediatric case of mesalazine-induced interstitial nephritis with
literature review
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Abstract We present the case of a 14-year-old boy with ulcerative colitis who was diagnosed with mesalazine-induced interstitial
nephritis (M-IIN). Improvement in renal function occurred with discontinuation of mesalazine and corticosteroid
therapy. We systematically searched the literature for pediatric cases of M-IIN. There were eight cases. Majority of the
cases were boys (75%) with ulcerative colitis (75%). Average duration of mesalazine use prior to the diagnosis of
interstitial nephritis was 24 18 months. The median dose was 1.5 g/day. M-IIN appears to be an idiosyncratic reaction
without any relation to dose or duration of mesalazine use. Although there are no guidelines to recommend routine
surveillance of renal function, monitoring of serum creatinine in patients on mesalazine remains an inexpensive and
non-invasive test that may lead to early detection and treatment of renal injury.
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Mesalazine has been used as first-line therapy for mild to mod-
erate inflammatory bowel disease (IBD). It is molecularly similar
to salicylates and phenacetin. Its mechanism of action in control-
ling IBD remains unclear. Although safe in general, mesalazine
use has been associated with fever, watery diarrhea, thrombocy-
topenia, pancreatitis, pneumonitis, and pericarditis.1 Among
these adverse drug-related events, interstitial nephritis is
a rare but serious complication of long-term mesalazine use.
The first reported association of interstitial nephritis with
5-aminosalicylates (5-ASA) was in 1992.2 Most reported cases of
mesalazine-associated interstitial nephritis are in adults. We
present an interesting case of mesalazine-induced interstitial
nephritis (M-IIN) in an adolescent patient with ulcerative colitis.
We provide further information on this rare condition by
presenting a systematic review of the few published case reports
of pediatric M-IIN in the literature.
Case Report
A 14-year-old boy with a 5-year history of ulcerative colitis
presented with a 2-week history of progressive fatigue, followed
by nausea and vague abdominal pain 5 days prior to admission.
His ulcerative colitis had been on clinical remission while on
mesalazine (1.5 g/day) for the past 3 years. Aside from ulcerative
colitis, the patient had no other medical history, no prior use of
non-steroidal anti-inflammatory drugs, or history of renal insuf-
ficiency. He reported having frothy non-foul-smelling urine
recently but denied dysuria, hematuria, or changes in his urinary
frequency. His vital signs were as follows: temperature 36.8°C,
blood pressure 90/60 mm Hg, heart rate 98 b.p.m., and respira-
tory rate 20 breaths/min. He had no focal abdominal tenderness,
rebound, guarding, flank, or suprapubic pain. He had grade 1
bipedal edema but no evidence of periorbital swelling or ana-
sarca. The patient was found to be in renal failure with the
following laboratory parameters: serum creatinine 11.9 mg/dL,
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urea 63 mg/dL, potassium of 4.8 mg/dL, and phosphorus
of 9 mg/dL. Hemoglobin was 10.3 g/dL, white cell count of
14.8 ¥ 103/mm3, absolute eosinophil count was 0.4 ¥ 103/mm3,
and platelets of 189 ¥ 103/mm3. Urinalysis showed 40/hpf
leukocytes without any eosinophiluria, hematuria or bacteriuria.
Proteinuria of 600 mg was detected in a 24-h urine collection.
The patient’s blood cultures were negative for both aerobic and
anaerobic bacteria. Screening serologic tests for HIV, viral hepa-
titis, herpes simplex virus, cytomegalovirus, and rickettsial dis-
eases were all negative. Mycobacterium tuberculosis infection
was ruled out by quantiferon testing. Rheumatologic screening
with anti-nuclear and double-stranded DNA autoantibodies was
negative. The ultrasound of the kidneys did not show evidence of
cortical atrophy, hydronephrosis, or nephrolithiasis. During his
initial hospital course, the patient received aggressive fluid resus-
citation and electrolyte management, resulting in slight improve-
ment of his serum creatinine to 9 mg/dL in 2 days. He underwent
renal biopsy, which showed active mononuclear infiltration
with scattered eosinophils, consistent with interstitial nephritis
(Fig. 1). Given the history of long-term mesalazine use, the his-
topathologic findings were consistent with mesalazine-associated
interstitial nephritis. Mesalazine was discontinued and the patient
was started on i.v. methylprednisolone (1 mg/kg/day) for 3 days.
He was discharged from the hospital with improvement of his
symptoms and was prescribed oral prednisone taper for 2 months.
His creatinine decreased to 1.4 mg/dL in 8 weeks. In spite
of discontinuing his mesalazine regimen, the patient con-
tinued to be in clinical remission in terms of his ulcerative
colitis.
Discussion
We conducted a systematic search on PubMed from January
1992 to November 2011 for pediatric cases of M-IIN, confirmed
by clinical, laboratory, and histopathologic criteria. We used the
following search terms: “5-aminosalicylic acid”, “mesalazine”,
“mesalamine”, “renal failure”, and “inflammatory bowel
disease” per the Cochrane collaboration search strategy. We
reviewed the bibliographies of our selected case reports for addi-
tional references. We retrieved eight pediatric cases of interstitial
nephritis associated with mesalazine use for the treatment of
IBD. Both authors independently extracted pertinent clinical
data, summarized in Table 1. The previously reported cases were
similar to our present case. Previously published pediatric cases
of M-IIN were predominantly in boys (n = 6; 75%), mean age
was 15.4  2.4 years old, and they had ulcerative colitis (n = 6;
75%). The baseline renal function in all patients was normal. All
patients presented with non-specific signs and symptoms, such as
fever, fatigue, weight loss, abdominal pain, nausea, and diarrhea,
prior to the diagnosis of interstitial nephritis. Urinalysis in all
patients was remarkable for proteinuria except for two cases,
which only reported white blood cells. There were only two cases
that reported the presence of eosinophils in urine.8 The finding of
eosinophiluria lacks sensitivity and specificity to either diagnose
or rule out interstitial nephritis.9 Renal ultrasound was abnormal
in four cases (50%), revealing increased renal cortical echogenic-
ity and decreased corticomedullary differentiation. Confirmatory
renal biopsy was reported in seven out of eight patients. The case
reported by Uslu et al.4 did not have histologic confirmation
because of the family’s refusal to consent for kidney biopsy.
Nevertheless, the patient’s clinical course and laboratory findings
were consistent with interstitial nephritis. In cases that reported
Fig. 1 Microscopic findings in the renal biopsy: mononuclear infil-
tration (lymphocytes) with scattered eosinophils in the interstitium
(Periodic acid-Schiff stain).
Table 1 Published reports of M-IIN in pediatric patients
Authors Age
(years)/sex
IBD
Type
Creatinine at
baseline (mg/dl)
Creatinine at
M-IIN diagnosis
(mg/dl)
5-ASA dose
(g/day)
5-ASA duration
(months)
Steroid
treatment
Outcome
Frandsen et al.3 17/M UC 0.7 24.6 2.4 48 No ESRD
Uslu et al.4 15/F UC 0.8 1.1 1.5 4 Yes Recovered
Arend et al.2 18/M UC 1 2.5 1.2 18 Yes Recovered
Skalova et al.5 15/M UC NR 1.43 3 48 Yes Recovered
Van Biervliet et al.6 11/F UC NR 0.88 1.5 36 Yes Recovered
Alivanis et al.7 19/M UC 1.2 7 NR 7 Yes Recovered
Benador et al.8 16/M CD NR 2.5 NR 6 Yes Recovered
14/M CD 0.8 1.4 NR 11 Yes Recovered
Current Patient 14/M UC 0.8 13.9 1.5 36 Yes Recovered
5-ASA, 5-aminosalicylates; CD, Crohn’s disease; ESRD, end-stage renal disease; IBD, inflammatory bowel disease; M-IIN, mesalazine-induced
interstitial nephritis; NR, not reported; UC, ulcerative colitis.
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mesalazine dose, the median was 1.5 g/day (range 1.2–3.0 g/
day). Average duration of mesalazine use prior to the diagnosis of
interstitial nephritis was 23.8 18.2 months. There were seven
cases that improved with discontinuation of mesalazine and
treatment with steroids, similar to our case. There was only
one case that developed end-stage renal disease, requiring
hemodialysis.3
Interstitial nephritis is a rare but potentially serious com-
plication of mesalazine use. An analysis of a prescription
database in the UK from 1991 to 1998 estimated about 11
reports of interstitial nephritis for every million prescriptions of
mesalazine.10 In terms of other 5-ASA products, a retrospective
analysis of the UK General Practice Research Database on
adult patients did not show any difference in the risk of
developing interstitial nephritis with other 5-ASA drugs, such
as balsalazide and olsalazine.11 However, there are no specific
studies in children comparing the incidence of interstitial
nephritis with mesalamine and other 5-ASA products. To our
knowledge, our systematic review is one of the few studies
to report 5-ASA-associated interstitial nephritis in pediatric
patients.
The mechanism of renal injury from mesalazine remains
unclear. There are preclinical studies linking aminosalicylates to
renal papillary necrosis but not directly with interstitial nephri-
tis. Based on animal models and clinical experience from
adult patients, M-IIN appears to be an idiosyncratic reaction
without any relation to the dose given to patients.2 Renal
insufficiency may also be a complication of IBD by itself.
Renal involvements in IBD may include: calcium oxalate stone
formation, nephrolithiasis, nephrocalcinosis, ureteric obstruc-
tion, immune complex glomerulonephritis, and secondary
amyloidosis.12 In our case report, the temporal association of
renal failure and recovery with the use and discontinuation
of mesalazine, respectively, is indicative of a drug-induced
mechanism rather than a primary IBD-associated process. In
contrast, failure to respond to mesalazine discontinuation
and steroid therapy are the hallmarks of IBD-associated renal
dysfunction.12
In our review of the published pediatric M-IIN cases, the
duration of 5-ASA use prior to the onset of acute renal injury
varied from 4 to 48 weeks (Table 1). This is similar to the onset
of other drug-induced interstitial nephritis where patients present
with either acute or subacute onset of non-specific symptoms,
such as malaise, anorexia, oliguria or nausea and vomiting. Based
on the kidney biopsy results, our case was diagnosed as acute
interstitial nephritis in the absence of chronic changes, such as
interstitial scarring, fibrosis or tubular atrophy. Also, the onset of
symptoms was only 2 weeks. Prior to this, the patient was asymp-
tomatic while on mesalazine for 3 years. Similar to most patients
with drug-induced interstitial nephritis, withdrawal of the offend-
ing drug and administration of steroids may show recovery of
renal function to normal or near-normal levels within a few
weeks.9
Although there are no standard guidelines to recommend
routine surveillance of renal function using serum creatinine
and urinalysis in IBD patients on mesalazine therapy, monitor-
ing of serum creatinine remains a simple, inexpensive, and a
non-invasive laboratory test which may detect and prevent pro-
gression of renal injury. Frandsen et al.3 suggested practical rec-
ommendations for measurement of serum creatinine prior to the
start of mesalazine treatment, followed by monthly monitoring
for the first 3 months, every 3 months for the next 9 months,
and every 6 months thereafter.
Conclusion
Mesalazine-induced interstitial nephritis is an infrequent but sig-
nificant adverse event that has occurred in pediatric IBD patients.
Early recognition of renal insufficiency may prevent further pro-
gression to end-stage renal disease. If detected early, discontinu-
ation of mesalazine and trial of corticosteroid therapy may
facilitate recovery of renal function.
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